Stock of the Day

August 11, 2021

PPD (PPD)

$47.28
$0.00 (0.0%)
Market Cap: $16.61B

About PPD

PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.

PPD Bull Case

Here are some ways that investors could benefit from investing in PPD, Inc.:

  • PPD, Inc. has a strong position in the biopharmaceutical industry, providing essential drug development services that are in high demand, particularly as the industry continues to grow.
  • The company has established a collaboration with Science 37, enhancing its capabilities in digital trials, which is a growing trend in clinical research, potentially leading to increased efficiency and cost savings.
  • PPD, Inc. operates through two segments—Clinical Development Services and Laboratory Services—allowing for diversified revenue streams and reducing dependency on a single market segment.
  • The current stock price of PPD, Inc. reflects a positive market sentiment, indicating investor confidence in the company's future growth prospects.
  • With a history of innovation and adaptation in drug development services, PPD, Inc. is well-positioned to capitalize on emerging trends and technologies in the healthcare sector.

PPD Bear Case

Investors should be bearish about investing in PPD, Inc. for these reasons:

  • The biopharmaceutical industry is highly competitive, and PPD, Inc. faces significant pressure from other established players, which could impact its market share and profitability.
  • Regulatory changes and compliance requirements in drug development can pose risks, potentially leading to increased operational costs and delays in project timelines.
  • Economic fluctuations can affect funding for biopharmaceutical projects, which may lead to reduced demand for PPD, Inc.'s services.
  • While the collaboration with Science 37 is promising, reliance on third-party technology can introduce risks related to execution and integration.
  • Investors should be cautious of potential volatility in stock performance, as the company’s financial health can be influenced by the success or failure of clinical trials and product approvals.

Recent News